Your browser doesn't support javascript.
loading
Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes.
Forlenza, Gregory P; Buckingham, Bruce A; Christiansen, Mark P; Wadwa, R Paul; Peyser, Thomas A; Lee, Joon Bok; O'Connor, Jason; Dassau, Eyal; Huyett, Lauren M; Layne, Jennifer E; Ly, Trang T.
Afiliação
  • Forlenza GP; 1 Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado.
  • Buckingham BA; 2 Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, California.
  • Christiansen MP; 3 Diablo Clinical Research, Walnut Creek, California.
  • Wadwa RP; 1 Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado.
  • Peyser TA; 4 ModeAGC LLC, Palo Alto, California.
  • Lee JB; 5 Insulet Corporation, Acton, Massachusetts.
  • O'Connor J; 5 Insulet Corporation, Acton, Massachusetts.
  • Dassau E; 6 Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts.
  • Huyett LM; 5 Insulet Corporation, Acton, Massachusetts.
  • Layne JE; 5 Insulet Corporation, Acton, Massachusetts.
  • Ly TT; 5 Insulet Corporation, Acton, Massachusetts.
Diabetes Technol Ther ; 21(5): 265-272, 2019 05.
Article em En | MEDLINE | ID: mdl-30925077
Background: The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm with variable glucose setpoints and moderate intensity exercise using an investigational device in adults with type 1 diabetes (T1D). Materials and Methods: A supervised 54-h hybrid closed-loop (HCL) study was conducted in a hotel setting after a 7-day outpatient standard treatment phase. Adults aged 18-65 years with T1D and HbA1c between 6.0% and 10.0% were eligible. Subjects completed two moderate intensity exercise sessions of >30 min duration on consecutive days: the first with the glucose set point increased from 130 to 150 mg/dL and the second with a temporary basal rate of 50%, both started 90 min pre-exercise. Primary endpoints were percentage time in hypoglycemia <70 mg/dL and hyperglycemia ≥250 mg/dL. Results: Twelve subjects participated in the study, with (mean ± standard deviation) age 36.5 ± 14.4 years, diabetes duration 21.7 ± 15.7 years, HbA1c 7.6% ± 1.1%, and total daily dose 0.60 ± 0.22 U/kg. Outcomes for the 54-h HCL period were mean glucose: 136 ± 14 mg/dL, percentage time <70 mg/dL: 1.4% ± 1.3%, 70-180 mg/dL: 85.1% ± 9.3%, and ≥250 mg/dL: 1.8% ± 2.4%. In the 12-h period after exercise start, percentage time <70 mg/dL was 1.4% ± 2.7% with the raised glucose set point and 1.6% ± 3.0% with reduced basal rate. The percentage time <70 mg/dL overnight was 0% ± 0% on both study nights. Conclusions: The Omnipod personalized MPC algorithm performed well and was safe during day and night use in response to variable glucose set points and with temporarily raised glucose set point or reduced basal rate 90 min in advance of moderate intensity exercise in adults with T1D.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicemia / Sistemas de Infusão de Insulina / Automonitorização da Glicemia / Diabetes Mellitus Tipo 1 / Hipoglicemiantes / Insulina Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicemia / Sistemas de Infusão de Insulina / Automonitorização da Glicemia / Diabetes Mellitus Tipo 1 / Hipoglicemiantes / Insulina Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2019 Tipo de documento: Article